Christoph Droogan, DO
Advanced Heart Failure and Transplant Cardiology · Wynnewood, PANPI 1174528129
Payments from drug & device makers
Across 416 payments — averaging $810.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$116K
- Boehringer Ingelheim$112K
- Abbott$46K
- Merck$23K
- Novartis$21K
- Daxor Corporation$7K
- plus $12K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 133 | $115,808 |
| Boehringer Ingelheim | 128 | $112,441 |
| Abbott | 46 | $45,586 |
| Merck | 25 | $23,472 |
| Novartis | 20 | $20,765 |
| Daxor Corporation | 6 | $6,965 |
| Bayer | 6 | $5,295 |
| Biotronik Inc. | 2 | $1,533 |
| Janssen Research & Development, LLC | 1 | $1,350 |
| Boston Scientific | 11 | $1,188 |
| Edwards Lifesciences | 2 | $1,012 |
| Abiomed | 6 | $468 |
| E.r. Squibb & Sons, L.L.C. | 6 | $290 |
| Actelion Pharmaceuticals US, Inc. | 6 | $156 |
| Impulse Dynamics (USA) Inc. | 1 | $143 |
| La Jolla Pharmaceutical Company | 1 | $139 |
| ZOLL Respicardia, Inc. | 1 | $132 |
| AstraZeneca | 5 | $129 |
| AbbVie | 3 | $100 |
| Pfizer | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| United Therapeutics Corporation | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $16 |
How this compares
$337,107 in reported general payments places this provider in the 80th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Wynnewood
- Steven DomskyWynnewood$1.1M
- John ClarkWynnewood$343K
- Anjali OwensPhiladelphia$1.7M
- Kenneth MarguliesPhiladelphia$1.7M
- Donald HaasAbington$1.4M
- Renee SangrigoliDoylestown$1.2M
- John BoehmerHershey$1M
- Anjali VaidyaPhiladelphia$805K
- Amresh RainaPittsburgh$767K
- Brendan CarryDanville$693K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.